Prognostic Significance of Nuclear Survivin Expression in Resected Adenoid Cystic Carcinoma of the Head and Neck

Adenoid cystic carcinoma (ACC) is an uncommon epithelial tumor that constitutes about 10% of all head and neck tumors. Unlike squamous cell head and neck cancer (HNSCC), ACC has been described as a tumor with indolent but persistent and recurrent growth and late onset of metastases, which eventually leads to death [1]. Several studies have identified clinicopathological factors in ACC with an unfavorable effect on survival, including old age, tumor location, advanced stage, solid histological subtype, high grade, major nerve involvement, the presence of perineural invasion, a positive surgical margin, and lymph node metastasis [2, 3]. The primary treatment for ACC is surgery, which is usually followed by post-operative radiotherapy. Although systemic chemotherapy has been used for recurrent or metastatic ACC, there is substantial doubt about its effectiveness and whether systemic therapy impacts on the disease course.

Additional predictors of ACC biologic activity might prove helpful for the clinical management of patients and could be a target of molecular therapy. Biologic prognostic factors including KIT, epidermal growth factor receptor, human epidermal growth receptor-2, estrogen and progesterone receptors, proliferating cell nuclear antigen, Ki-67, and the p53, bcl-2 and SOX-4 genes, have been extensively investigated and are candidates for targeted therapy [4]. However, the results from studies on the effectiveness of several molecular targeted therapies for salivary gland ACC have been disappointing. Thus, more studies are needed for current molecular targeted therapy and further research into novel molecular targets is urgently necessary.

Survivin is one of the most cancer-specific proteins identified to date. It belongs to the apoptosis inhibitor gene family, in which the proteins are characterized by a domain of about 70 amino acids, termed baculovirus inhibitor of apoptosis proteins (IAPs) repeat (BIR) [5]. Unlike other IAPs, survivin is small and has only a single N-terminal BIR domain, a long C-terminal alpha-helix coiled region, and forms a stable dimmer in solution. It inhibits apoptosis differently than bcl-2 either by directly or indirectly interfering with caspase-3 and caspase-7 function via its BIR domain. Survivin also counteracts cell death by interfering with caspase-9 processing, the upstream inhibitor in the intrinsic pathway of apoptosis [6]. Furthermore, survivin enhances cell proliferation and promotes angiogenesis. Survivin is expressed during embryonic and fetal development but is undetectable in terminally differentiated normal adult tissue. However, it is re-expressed in transformed cell lines and several human cancer cells at a frequency of 34-100% [7]. High survivin expression is significantly associated with poor clinical outcomes in various cancers [8–13], including HNSCC [12]. Thus, because of its upregulation in malignancy, it has become of great interest as both a tumor diagnostic and prognostic marker, as well as a new substantial biologic target for future anti-cancer therapies [14]. However, survivin expression in patients with head and neck ACC has not been studied. Moreover, the impact of survival on clinicopathological characteristics and prognosis is unknown.

We investigated the degree of proliferative activity using Ki-67 and the expression of other apoptosis related proteins, bcl-2 and p53. Ki-67 is a nuclear antigen expressed mainly in the S and M phases of the cell cycle, and it has been used for estimating the growth fraction in many studies investigating various tumor types and also in a variety of malignant salivary gland tumors [15]. Bcl-2 proteins play a key role in preventing programmed cell death by favoring prolonged survival in normal and neoplastic cells [16]. The bcl-2 oncoprotein is also proving useful as an investigative tool in oral pathology [17]. Similarly, the p53 protein stimulates the transcription of several genes that mediate cell cycle arrest, and this protein initiates apoptosis in response to DNA damage. While the wild-type p53 protein makes tumor differentiation possible, the mutant p53 protein blocks it [18].

Thus, in the present study, we examined survivin expression in surgical specimens from patients with head and neck ACC using tissue microarray and immunohistochemical methods. We also investigated survivin expression in patients with head and neck ACC and its association with other biologic markers and clinical outcomes.

We examined survivin expression in patients who underwent resection for head and neck ACC. The nuclear expression of survivin, which was more frequently observed in larger tumors, was significantly correlated with unfavorable clinical outcome. To the best of our knowledge, this study is the first to demonstrate a significant correlation between survivin expression and clinical prognosis in patients with resected ACC of the head and neck. These data suggest that nuclear survivin expression aggressively identifies cases of head and neck ACC and, therefore, could influence the decision for therapy at the time of diagnosis.

Several studies have identified clinicopathological factors with an unfavorable effect on survival in ACC, including old age, tumor location, advanced stage, solid histological subtype, high grade, major nerve involvement, the presence of perineural invasion, and the presence of a positive surgical margin [2]. In our previous report, only lymph node involvement was predictive of overall survival [3]. However, using conventional clinopathological criteria, it is difficult to develop an accurate prognosis and treatment response for advanced head and neck ACC. When we analyzed the survival biomarkers in this study, a stepwise Cox analysis showed that nuclear survivin was significantly associated with survival. When we analyzed the survival biomarkers in this study, a stepwise Cox analysis showed that nuclear survivin was significantly associated with survival.

Survivin has been studied as a prognostic marker in various cancers. Patients with survivin-positive tumors have a decreased apoptotic index and worse survival rates than those with survivin-negative tumors. In addition, survivin expression has been correlated with resistance against chemotherapy- and radiotherapy-induced apoptosis and abbreviated patient survival [14]. Previous studies have correlated survivin with an unfavorable clinical outcome in a variety of cancers, including colorectal cancer [8], breast cancer [9], lung cancer [10], esophageal cancer [11], brain tumor [13], soft tissue sarcoma [19], and hematologic malignancies [20].

In the present study, with a median follow-up time of 83.5 months, patients with high nuclear survivin expression had poorer overall survival than those with low nuclear survivin expression (median duration, 120.8 vs. 192.5 months; hazard ratio, 8.567; 95% CI, 1.445- 50.783; P = 0.018). Moreover, survivin expression, especially subcellular nuclear localized expression, was a strong independent negative predictor of overall survival. Little data exist on the expression or clinical implications of survivin in head and neck ACC. On the contrary, the clinical significance of survivin expression in HNSCC has been reported for oral [21], oropharyngeal [22], and laryngeal carcinoma [23]. Our results are supported by several reports. Lo Muzio et al. [21], in a series of 110 oral SCC cases, found that patients with low survivin expression had significantly better survival rates than patients with medium and high survivin expression. Presuss et al. [22] showed that nuclear survivin expression was associated with a poor overall survival rate, with an estimated 3-year overall survival probability of 17.3% vs. 87.4% for non-nuclear expression of survivin (p < 0.001) in 73 patients with surgically treated oropharyngeal SCC. Dong et al. [23] examined 102 cases of laryngeal SCC, and found that survivin expression was significantly associated with shorter disease-free and overall survival (hazard ratio, 0.2696; 95% CI, 0.02666-0.85475; P 0.05).

In contrast, Freier et al. [24] found that high survivin expression was associated with increased 3-year, 5-year, and 10-year overall survival in tumors from 296 patients with advanced oral SCC who were treated with radiotherapy (P = 0.005, P = 0.004 and P = 0.002, respectively). The authors concluded that high survivin expression might be useful for identifying patients with oral SCC who could benefit from radiotherapy. These inter-report differences may be associated with the histological tumor types, different treatment modalities, the various immunohistochemistry protocols and/or antibodies used, or be due to variable criteria applied to annotate a tumor as nuclear- or cytoplasmic-survivin positive. In fact, Freier et al. did not analyze nuclear and cytoplasmic staining to categorize immunostaining independently.

Survivin exists in distinct nuclear and cytoplasmic subcellular pools in human cancer cells [25]. However, the clinical implications for subcellular localization of survivin expression remains controversial. Among the 19 publications relevant to survivin localization in nuclei or cytoplasm in various cancer tissues reviewed by Li et al. [26], 9 showed that survivin expression in cancer cell nuclei was an unfavorable prognostic marker, whereas 5 proposed the opposing notion that nuclear survivin expression represented a favorable prognostic marker. Similarly, overall survivin expression, its discrete intracellular localization, and its implication as a prognostic marker were also analyzed in several HNSCC studies, albeit with opposing results [12, 22, 27]. In a series of nine patients with laryngeal basaloid squamous cell carcinoma, Marioni et al. [12] found that high nuclear survivin expression is associated with disease recurrence and poor prognosis (P = 0.02). Khan et al. [27] did not find a significant correlation between the survivin expression pattern and clinicopathological parameters in patients with oral SCC. Lo Muzio et al. [21] in a series of 110 cases of oral SCC, found a significant correlation between the cytoplasmic survivin expression pattern and poor clinical outcome. Recently, four alternatively splicing transcripts have been identified in a single copy of the survivin gene. In addition to wild-type survivin, four survivin variants (survivin-2A,-2B,-3B and -ΔEx3) are generated [28]. These transcripts may have different subcellular localizations. All transport occurs through the nuclear pore multiprotein complex. Recent convincing experimental data suggest that survivin contains Crm1-dependent nuclear export signals (NES) in the linker region between the BIR domain and the C-terminal alpha helix. Consistent with this finding, the NES-deficient survivin isoforms survivin-ΔEx3 and survivin-2A do not localize predominantly in the cytoplasm, whereas the NES-containing variants survivin-2B and survivin-3B are cytoplasmic [29]. Nuclear survivin is also a subunit of the chromosomal passenger complex, which ensures the correct completion of cytokinesis and is composed of the mitotic kinase aurora-B, borealin, and INCENP [30]. However, their functions in carcinogenesis are largely unknown, and why survivin displays a predominant nuclear localization in some tumors but not in others is unclear. Functionally, one could consider that the nuclear pool of survivin is involved in promoting cell proliferation in most cases, whereas cytoplasmic survivin may participate in controlling cell survival but not cell proliferation. Nuclear survivin may help maintain the integrity of the mitotic spindle in cancer cells [30], and strong nuclear survivin staining may represent an increased number of mitotic events, resulting in poor survival [10]. In many immunohistochemical studies, nuclear survivin expression is an unfavorable factor for prognosis, including prostate cancer [31], rectal cancer [32], esophageal squamous cell carcinoma [11], colorectal carcinoma [8], soft-tissue sarcoma [19], breast cancer [9], laryngeal squamous cell carcinoma [12], hepatocellular carcinoma [33], ovarian carcinoma [34], non-small cell lung carcinoma [10], and glioblastoma [13]. In contrast, few studies have reported immunohistochemical cytoplasmic survivin expression as an unfavorable factor in patients with colorectal cancer [30], pancreatic cancer [35], or oral squamous cell carcinoma [21]. Thus, further investigations are required to clarify the prognostic value of nuclear/cytoplasmic survivin expression.

In this study, nuclear and cytoplasmic survivin was highly expressed in 62.2% and 83.8% of the ACC specimens, respectively. Similarly, in HNSCC, despite the use of variable cut-off values, previous studies have reported that survivin is expressed in 12% to 72% of patients with HNSCC [27, 36]. The analysis of survivin and the clinicopathological factors showed a significant association between tissue expression of survivin and tumor size but not lymph node involvement, which has also been observed in previous studies on other cancers, including laryngeal cancer [23]. The correlation between survivin expression and tumor stage or the presence of lymph node metastases in patients with primary HNSCC is still a matter of debate. In Khan et al., there was no significant association between survivin and tumor stage. Considering lymph node metastasis, Marioni et al. [36], in an evaluation of 13 consecutive cases of oral and oropharyngeal SCC with pN+ and 13 cases of pN0, demonstrated that eight patients in the pN+ group were survivin-positive (mean expression 34.7%), compared to five in the pN0 group (12.3%), and this difference was statistically significant (P = 0.017). In contrast, Lo Muzio et al. [21], in an analysis of 110 oral SCC cases, reported that there was no significant correlation between survivin expression and the presence of lymph node metastases.

We found that the association between survivin expression and bcl-2 was correlated statistically (nuclear expression, P = 0.031; cytoplasmic expression, P = 0.078). The bcl-2 oncoprotein is a potent inhibitor of apoptosis and is overexpressed in a wide variety of malignancies, including salivary gland tumors [17]. One of antiapoptotic mechanisms by which bcl-2 may mediate cell cytoprotection independently of cytochrome c release is through increased survivin expression [37]. However, we did not find significant correlations between survivin and p53 or ki-67 expression. Khan et al. [27], in a series of 29 oral SCC cases, observed that about half of the p53-positive oral SCC and premalignant tissues also showed significant survivin positivity. Furthermore, Ki-67 was expressed at a rate of 10.8%, in contrast to that of survivin. This relatively low expression Ki-67 rate may explain the indolent natural course of head and neck ACC [38]. Ki-67 values greater than 10% have been demonstrated to be the most significant indicator of short-term clinical course in ACC [39].

The present study has several limitations. First, it was a relatively small number of patients. Second, we measured expression using only immunohistochemical staining, which has several weak points, including a semiquantitative nature, tissue aging effects, the staining technique, the enzyme antibody used, and single observer bias.

In conclusion, the present study demonstrated that nuclear survivin expression has clinicopathological implications in patients with head and neck ACC. We expect that our data on the clinical implications of survivin will provide new insights into the management of head and neck ACC. Survivin may be an ideal target for therapy to improve the prognosis of patients with head and neck ACC. Further investigation is necessary to clarify and understand the roles of survivin in patients with head and neck ACC.